Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Key Inclusion Criteria:

Documented evidence of hormone receptor-positive human epidermal growth factor receptor 2 negative (HER2-negative) (hormonal receptor-positive (HR+)/HER2-) metastatic breast cancer (MBC) confirmed

Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for MBC including:

At least 1 prior anticancer hormonal treatment.
At least 1 cyclin-dependent kinase inhibitor 4/6 in the metastatic setting.
Eligible for one of the chemotherapy options listed in the TPC arm
Documented disease progression after the most recent therapy
Adequate bone marrow function (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500 per mm^3, platelets ≥ 100,000 per mm^3).
Adequate renal function: calculated creatinine clearance ≥ 30 mL/minute according to the Cockcroft and Gault formula
Adequate hepatic function (bilirubin ≤ 1.5 institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x IULN or 5.0 x IULN)
Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin (ß-hCG))

Key Exclusion Criteria:

Previous treatment with topoisomerase 1 Inhibitors as a free form or as other formulations
History of significant cardiovascular disease or clinically significant electrocardiogram (ECG) abnormality
Individuals with Gilbert's disease.
Active serious infection requiring antibiotics
Individuals with a history of an anaphylactic reaction to irinotecan
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Locally advanced MBC (stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.